Ubamatamab, Anti-PD-1 ICI, May Bolster Immune Response in Kidney CancerByPavlos Msaouel, MD, PhDJuly 27th 2024A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.